Thursday, January 20, 2022 10:03:05 AM
biosectinvestor, I do agree that NWBio has been much more upfront and open when talking about Advent and the MHRA. I believe this is due to the quiet period. Because of the quiet period, NWBio is not talking about anything related to the DCVax-L trial, their discussions with the FDA, and the status of their DCVax-L manufacturing agreement with Cognate/CRL.
Because of the quiet period, it is ok for NWBio to openly PR and discuss all thing related to Advent and the MHRA, without violating the quiet period and discussing anything specifically related to the DCVax-L trial. I believe that if NWBio were to tell us that they are currently in talks with Cognate/CRL to update the terms of their DCVax-L CDMO agreement, that would indirectly give us information about the results and status of the DCVax-L clinical trial, and would also indirectly give us information about their discussions with the FDA. That would indirectly violate the quiet period.
I do believe that Advent and the UK are important, but I think they are also a useful and convenient “red herring”. These are all my opinions.
Because of the quiet period, it is ok for NWBio to openly PR and discuss all thing related to Advent and the MHRA, without violating the quiet period and discussing anything specifically related to the DCVax-L trial. I believe that if NWBio were to tell us that they are currently in talks with Cognate/CRL to update the terms of their DCVax-L CDMO agreement, that would indirectly give us information about the results and status of the DCVax-L clinical trial, and would also indirectly give us information about their discussions with the FDA. That would indirectly violate the quiet period.
I do believe that Advent and the UK are important, but I think they are also a useful and convenient “red herring”. These are all my opinions.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
